Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Intuitive Surgical stock costs EUR 382.35 as Q2 revenue rose 19 percent

Earnings report AI-generated analysis

πŸ“ˆ Intuitive Surgical reported second-quarter revenue of USD 2.89 billion, marking a 19 percent year-over-year increase.

πŸ’° GAAP net income for the quarter reached USD 818.10 million, compared to USD 658.00 million in the prior year.

πŸ”§ Total procedures increased by 16 percent, with da Vinci procedures up 15 percent and Ion procedures surging 36 percent.

πŸ“… The company is scheduled to report third-quarter results on October 20, 2026, with consensus revenue estimates of USD 2.91 billion.

🌍 Recurring revenue reached USD 2.47 billion, representing 85 percent of second-quarter sales and highlighting a stable business model.

πŸ“Š Intuitive Surgical maintained its full-year da Vinci procedure growth guidance range of 13.50 percent to 15.50 percent for 2026.

πŸ₯ A meta-analysis covering 13 benign conditions found improved patient outcomes associated with da Vinci surgery, reinforcing clinical value.

πŸ“ˆ The stock traded at EUR 382.35 on October 19, 2026, ahead of the Q3 earnings release.

🌐 International business and recurring revenue remain key indicators for sustaining growth after U.S. da Vinci growth moderated to 12 percent.

Bullish Signals
  • Intuitive Surgical achieved a robust 19 percent year-over-year increase in second-quarter revenue, reaching USD 2.89 billion.
  • GAAP net income grew significantly to USD 818.10 million from USD 658.00 million a year earlier, demonstrating strong profitability.
  • Total procedures expanded by 16 percent, driven by a 36 percent surge in Ion procedures and 15 percent growth in da Vinci systems.
  • The company maintained its full-year guidance for da Vinci procedure growth between 13.50 percent and 15.50 percent for 2026.
  • Recurring revenue accounted for 85 percent of second-quarter sales at USD 2.47 billion, indicating a stable and predictable cash flow base.
  • A meta-analysis confirmed improved patient outcomes with da Vinci surgery across 13 benign conditions, supporting long-term clinical adoption.
Full Analysis
Intuitive Surgical reported strong second-quarter financial results, with revenue reaching USD 2.89 billion, representing a 19 percent year-over-year increase. GAAP net income for the quarter was USD 818.10 million, up from USD 658.00 million in the same period last year. The company's stock traded at EUR 382.35 on October 19, 2026, ahead of its scheduled third-quarter earnings report on October 20. Operational growth was driven by a 16 percent increase in total procedures performed, with specific gains in both the da Vinci and Ion robotic systems. Da Vinci procedures grew by 15 percent while Ion procedures saw a significant 36 percent surge. The company maintains its full-year guidance for da Vinci procedure growth between 13.50 percent and 15.50 percent for 2026, indicating confidence in sustaining momentum despite recent moderation in the U.S. market. Recurring revenue remains a critical component of Intuitive Surgical's business model, accounting for 85 percent of second-quarter sales at USD 2.47 billion. The company highlighted a meta-analysis covering 13 benign conditions that demonstrated improved patient outcomes associated with da Vinci surgery. Analysts are closely watching whether procedure growth can remain near the guidance range as international business and recurring revenue streams continue to serve as key indicators for future performance. Intuitive Surgical operates in the healthcare medical instruments and supplies sector, listed on Nasdaq under ticker ISRG. The company's headquarters is located in Sunnyvale, where it maintains a modern campus. With the upcoming Q3 report expected to show USD 2.91 billion in consensus revenue, investors will be evaluating if the recent growth trajectory can be sustained globally.